Upcoming Phase 2 Data Expected For Longeveron’s (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer’s Sector â€" What To Look For -Today at 09:26 am
By David Willey, BenzingaLongeveron , a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its...
Source: marketscreener.com